Vivos Therapeutics Announces Registration with Health Canada to fabricate and promote tools for sleep disorders, snoring and sleep apnea to Canadian dentists

HIGHLANDS RANCH, Colo., December 9, 2021 (GLOBE NEWSWIRE) – Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, today announced its official registration with Health Canada, a department of health responsible for maintaining and improving the health of Canadians through services and resources. The official registration of Vivos products is intended to provide patients with a comprehensive end-to-end solution for OSA patients that includes clinical screening, medical diagnosis and therapy with Vivos products.

At the center of this development, the company will offer its full line of highly effective oral devices and proprietary clinical protocols to approximately 25,000 dentists across Canada who have of patients looking for a solution to sleep disorders, snoring and OSA.

“With Vivos Therapeutics as an official Health Canada partner, local dentists can now examine, clinically assess and properly treat patients with OSA through full and official access to the Vivos system. For years, Canadian dentists have been in demand for our revolutionary line of products and now we can be aggressive with this new development to provide them with the full level of clinical and practice management training to seamlessly serve our much-needed products to all of the of Canadians suffering of OSA and its associated comorbidities, ”said Kirk Huntsman, chairman and CEO of Vivos.

In light of this regulatory move, Vivos expects to expand its contract manufacturing presence and capabilities in Canada to better serve the needs of Canadian dentists and their patients.

“As a senior dentist at Avalon Dental and an investigator on a pediatric clinical trial with Vivos WCG IRB, I have spent years trying to find alternative treatments for my patients who suffer from a range of sleep disorders. With the Vivos system, I can finally officially prescribe the latest therapeutic protocol and technology that I believe will improve my patients’ clinical outcomes, ”said Dr. Tammarie Heit from Edmonton, Alberta, Canada.

The story goes on

About Vivos Therapeutics, Inc.

Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients with mild to moderate obstructive sleep apnea (OSA). Vivos treatment includes bespoke oral devices and treatment protocols called the Vivos system. Vivos believes that the Vivos System oral appliance technology is the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for adults with mild to moderate OSA. Vivos also sells orthodontic equipment for adults and children. Vivos oral appliances have been shown to be effective on over 22,000 patients treated by more than 1,350 trained dentists worldwide.

By combining proprietary technologies and protocols that change the size, shape, and position of the tissue that makes up a patient’s upper airway, the Vivos system opens the airway space and can detect symptoms and conditions related to mild to moderate OSA, such as index scores . Vivos also markets and sells VivosScore-supported SleepImage diagnostic technology for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dental training and other value-added services related to the use of the Vivos system.

More information is available at

Cautionary Note Regarding Forward-Looking Statements

This press release and related management statements contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) about future events, in particular with regard to the public offer described here. Words like “aim”, “could”, “could”, “expect”, “project”, “intend”, “plan”, “believe”, “forecast”, “anticipate”, “hope”, “estimate” and Variations on such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based on several assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the anticipated benefits of the Company’s relationship with Candid Care described herein) could differ materially from those expressed or implied in such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings are available free of charge on the SEC’s website at Except to the extent required by law, Vivos expressly disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statements contained herein in order to reflect changes in Vivos’ expectations therewith or changes in events, conditions or circumstances on which any statement is based.

Vivos Investor Relations contact:
Julie Gannon
Investor Relations Officer

Vivos Media Relations Contact:
Francesca DeMauro / Jenny Robles
KCSA Strategic Communication
(917) 880-9771 / (212) 896-1231 /

Leave a comment

Your email address will not be published. Required fields are marked *